Latest News

Navepegritide becomes the first and only once-weekly treatment to increase linear growth in children with achondroplasia.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Launching sustainable, effective CGT programs requires a roadmap for strategy, operations, access, finance, quality, and pharmacy.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Pegvaliase becomes the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in patients with phenylketonuria.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Oral bacteria like Fusobacterium nucleatum may fuel breast cancer—here's what pharmacists should know about periodontal health and genetic risk.

FDA priority review of rusfertide signals a new PV option, cutting phlebotomy reliance and improving hematocrit control, with pharmacists guiding injections and safety.

Somapacitan-beco becomes the first and only once-weekly growth hormone approved for children with idiopathic short stature, those born small for gestational age, and those with Noonan syndrome, offering an alternative to daily injections.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

A practical look at redesigning tasks and integrating artificial intelligence to improve efficiency and patient outcomes

Add beans and legumes to your diet for better health: Boost fiber and key nutrients while improving blood glucose, heart health, digestion, and weight control.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.